Form 4: Lantern Pharma CFO David Margrave Acquires 52,000 Stock Options

David R. Margrave, CFO of Lantern Pharma Inc., reports the acquisition of 52,000 stock options on July 15, 2024.

Summary

• On July 15, 2024, David R. Margrave, the Chief Financial Officer of Lantern Pharma Inc., acquired 52,000 stock options.
• The options have an exercise price of $4.35.
• These options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• The options vest in equal monthly increments over a 24-month period, starting August 15, 2024.
• The expiration date for these options is July 15, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing about stock option grants. It doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by the CFO could indicate confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry. It provides transparency into the actions of company executives.

Stakeholder Impact

• The acquisition of stock options by the CFO could be viewed positively by shareholders as it aligns the CFO's interests with the company's success.

Key Dates